Hemostemix Inc.
HMTXF
$0.04
$0.000.80%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 75.54% | -84.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -71.80% | 28.98% | |||
| Operating Income | 71.80% | -28.98% | |||
| Income Before Tax | 69.79% | -420.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 69.79% | -420.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 69.79% | -420.39% | |||
| EBIT | 71.80% | -28.98% | |||
| EBITDA | 71.79% | -28.98% | |||
| EPS Basic | 59.30% | -244.00% | |||
| Normalized Basic EPS | 61.54% | -41.30% | |||
| EPS Diluted | 59.30% | -244.00% | |||
| Normalized Diluted EPS | 61.54% | -41.30% | |||
| Average Basic Shares Outstanding | -24.96% | 48.69% | |||
| Average Diluted Shares Outstanding | -24.96% | 48.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||